Verrica Pharmaceuticals Inc.

08/27/2026 | Press release | Distributed by Public on 08/27/2026 06:02

Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.
Verrica Pharmaceuticals Inc. published this content on August 27, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on August 27, 2026 at 12:04 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]